Lifeward Ltd. (LFWD)
Nasdaq: LFWD · Orthopedic, Prosthetic & Surgical Appliances & Supplies · Marlborough, MA · filing with the SEC since 2014
Filings
427 filings since 2017 beside 270 insider forms · Non-accelerated filer and smaller reporting company · read from EDGAR on Nov 13, 2026Due nextNon-accelerated filer and smaller reporting company
10-K
Annual report for the fiscal year ending Dec 31, 2026Non-accelerated filers and smaller reporting companies have 90 days after the fiscal year ends.
by Mar 31, 2027
10-Q
Quarterly report for the quarter ending Mar 31, 2027Non-accelerated filers and smaller reporting companies have 45 days after the quarter ends; quarter ends are taken to the month end.
by May 15, 2027
A deadline is the latest date the SEC's rules allow for its filer category. It is not a forecast of the day the company files. Last time, the results release (8-K item 2.02) came 44 days after the quarter ended. The proxy statement was last filed Sep 25, 2026.
Filings a yearinsider forms included
6385658173447077
2026 counts to Nov 13, 2026.
Officer or director change (8-K item 5.02): 23 times in the last 36 months, the newest Oct 27, 2026.Listing warning from its exchange (8-K item 3.01): 2 times in the last 36 months, the newest Mar 20, 2026.SEC letters: 9 in the last 36 months, the newest May 8, 2026.A late-filing notice, Form NT 10-Q, filed May 15, 2026.
Insider forms (3, 4, 5 and 144) are counted each year but not listed here; the people and their trades are on the Ownership tab.
FiledFormWhat it is, in plain wordsPeriodAsk
Nov 13, 2026
8-K items 2.02, 9.01
Results released · Current reportThe SI's read Lifeward reported third quarter 2026 revenue of $5.4 million, down 12% from $6.2 million, as ReWalk exoskeleton sales fell to $1.7 million during a shift to selling through partners, while AlterG revenue rose 18% to $3.6 million. Gross margin dropped to 27.4% from 43.7%, operating expenses rose to $7.5 million and the net loss widened to $5.1 million from $3.2 million. Falling sales, thinner margins and a wider loss make the quarter concerning, though cash rose to $4.5 million from $2.2 million at the end of 2025.
Nov 13, 2026
10-Q
Quarterly reportThe SI's read Lifeward reported third quarter revenue of $5,428 thousand, down from $6,195 thousand, and a net loss of $5,052 thousand against $3,170 thousand, with a nine month net loss of $27,364 thousand as research spending on the acquired ORMD-0801 oral insulin program and financing charges rose. The company held $4,548 thousand in cash at September 30, 2026, carried $7,133 thousand of convertible notes, and lists its ability to continue as a going concern, meaning to keep paying its bills for the next twelve months, among its risks. The tag is concerning because sales fell, losses widened and cash is thin.
Sep 30, 2026
Aug 14, 2026
8-K items 2.02, 5.02, 9.01
Results released; Officer or director change · Current report
Aug 10, 2026
Jul 7, 2026
8-K items 1.01, 2.03, 3.02, 9.01
Major agreement signed; New debt or obligation taken on; Shares sold without registration · Current report
Jun 30, 2026
Mar 25, 2026
8-K items 2.01, 3.02, 5.02, 9.01
Purchase or sale of a business completed; Shares sold without registration; Officer or director change · Current report
40 of 427 shown
Every row opens the filing on EDGAR. The plain words are the site's own for each form and each 8-K item; the complete history, insider forms included, is on EDGAR.